Methods for using transcription-dependent directed evolution of AAV capsids
The TRADE system addresses the challenge of selecting AAV vectors for specific cell types by using transcription-dependent evolution, achieving enhanced transduction efficiency and liver detargeting in non-human primates, surpassing previous methods.
Patent Information
- Application Number
- JP2024113548
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-31
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for selecting adeno-associated virus (AAV) vectors for gene therapy face challenges in efficiently targeting specific cell types, particularly in non-human primates, due to the lack of Cre transgenic animals and high background recoveries of ineffective variants, limiting the development of clinically relevant vectors.
The Transcription-dependent Directed Evolution (TRADE) system selects AAV capsids based on cell type-specific mRNA expression without requiring Cre recombinase, allowing for flexible and stringent selection of AAV vectors in various animal species, including non-human primates, by using antisense mRNA driven by enhancer-promoters.
TRADE enables the identification of AAV capsids that transduce neurons and other cell types more efficiently than existing vectors, with up to 18 times better performance in mice and non-human primates, and demonstrates liver detargeting properties, overcoming limitations of previous methods.
Smart Images

Figure 2024161365000001_ABST
Abstract
Description
[Technical field]
[0001] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with Government support under No. NS088399 awarded by the National Institutes of Health / National Institute of Neurological Disorders and Stroke. The Government has certain rights in this invention.
[0002] The present disclosure relates to viral vectors used for gene transfer. More specifically, the present disclosure relates to a method for transcription-dependent directed evolution and adeno-associated viral ("AAV") vectors selected by using the method. [Background technology]
[0003] Recombinant adeno-associated virus ("AAV") vectors are among the most promising for in vivo gene transfer. The utility of AAV vectors has expanded since many naturally occurring novel serotypes and subtypes have been isolated from human and non-human primate tissues. Gao et al., J Virol 78, 6381-6388 (2004) and Gao et al., Proc Natl Acad Sci USA 99, 11854-11859 (2002). Among the newly identified AAV isolates, AAV serotype 8 (AAV8) and AAV serotype 9 (AAV9) have attracted attention because AAV vectors derived from these two serotypes can transduce various organs, including the liver, heart, skeletal muscle and central nervous system, with high efficiency after systemic administration. Ghosh et al., Mol Ther 15, 750-755 (2007); Pacak et al., Circ Res 99, 3-9 (2006); Inagaki et al., Mol Ther 14, 45-53 (2006); Zhu et al., Circulation 112, 2650-2659 (2005); Wang et al., Nat Biotechnol 23, 321-328 (2005); Nakai et al., J Virol 79, 214-224 (2005); and Foust et al., Nature Biotechnol 23, 321-328 (2009). This stable transduction by AAV8 and AAV9 vectors was attributed to a strong tropism for these cell types, efficient cellular uptake of the vectors, and / or rapid uncoating of the virion shell in the cells. Thomas et al., J Virol 78, 3110-3122 (2004). In addition, the emergence of AAV vectors engineered with better capsids has greatly expanded the utility of AAV as a vector toolkit. Asokan et al., Mol Ther 20, 699-708 (2012).
[0004] Proof of concept using AAV-mediated gene therapy has been demonstrated in a number of preclinical animal models of human disease. Phase I / II clinical studies have shown promising results for the treatment of hemophilia B (Nathwani et al., N Engl J Med 71, 1994-2004 (2014)), lipoprotein lipase deficiency (Carpentier et al., J Clin Endocrinol Metab 97, 1635-1644 (2012)), Leber congenital amaurosis (Jacobson et al., Arch Ophthalmol 130, 9-24 (2012) and Pierce and Bennett, Cold Spring Harb Perspect Med 5, a017285 (2015)), among others (published in Mingozzi and High, Nat Rev Genet 12, 341-355 (2011) and Wang et al., Nat Rev Drug Discov 18, 358-378 (2019)).
[0005] Despite this promise, human studies have further revealed unexpected problems and potential difficulties with AAV-mediated gene therapy. Manno et al., Nat Med 12, 342-347 (2006). In addition, despite breakthroughs in our understanding of AAV biology and capsid-phenotype relationships (Adachi et al., Nat Commun 5, 3075, (2014); Grimm et al., Hum Gene Ther 28, 1075-1086, (2017); and Ogden et al., Science 366, 1139-1143, (2019)), there remain many desirable properties of clinical AAV vectors that we cannot rationally design.
[0006] To this end, high-throughput screening methods have been used to identify new AAV capsids with such desirable phenotypes. Specifically, the development of in vivo AAV library selection strategies has produced a variety of designer AAV mutants (published in Kotterman and Schaffer, Nat Rev Genet 15, 445-451 (2014) and Grimm et al., Mol Ther 23, 1819-1831 (2015)) that are competent for highly efficient transduction of previously resistant cell types.
[0007] The earliest attempts at in vivo library selection (first generation) relied on the recovery of vector genomic DNA from dissected tissue. In theory, this strategy allows the recovery of both effective as well as some mediating AAV variants, but not all steps are required for vector-mediated transgene expression (Figure 1). Thus, screening of diverse libraries of synthetic AAV variants causes high background recovery of AAV variants that in some cases are completely ineffective gene therapy vectors. Furthermore, targeting specific cell types requires further processing such as fluorescence-activated cell sorting or laser capture microdissection. Nevertheless, there have been several reports of successful use of this technique. Excoffon et al., Proc Natl Acad Sci USA 106, 3865-3870 (2009); Grimm et al., J Virol 82, 5887-5911 (2008); Lisowski et al., Nature 506, 382-386 (2014); and Dalkara et al., Sci Transl Med 5, 189ra176 (2013). However, the landmark work of Deverman et al. in 2016 showed that this process can be significantly improved by the use of a Cre-dependent selection strategy (second generation). Deverman et al., Nat Biotechnol 34, 204-209 (2016). Cre-dependent library selection takes advantage of the selective ability of Cre recombinase to act on double-stranded DNA rather than single-stranded DNA to reverse vector genomic DNA containing primer binding sequences. This sequence inversion allows orientation-selective PCR to specifically amplify viral DNA delivered to cells by AAV mutants that can undergo a late stage of transduction in which double-stranded DNA is formed from the single-stranded AAV genome. Furthermore, the use of Cre driver lines allows the selection of new AAV mutants that transduce efficiently and promotes selective gene expression of Cre recombinase in a cell type-specific manner.Indeed, the use of Cre-dependent selection allowed the authors to develop an AAV9 variant, AAV-PHP.B, that is 40-fold more capable of transducing than the parental AAV9 after systemic administration in C57BL / 6J mice. Deverman et al., Nat Biotechnol 34, 204-209 (2016). Unfortunately, it has recently become clear that the enhancement shown by AAV-PHP.B in mice does not translate to non-human primates (Matsuzaki et al. 2018 and Hordeaux et al. 2019). Surprisingly, the enhancement does not even extend to all commonly used mouse strains (Matsuzaki et al. 2018 and Hordeaux et al. 2019). Thus, there is a strong impetus to accelerate the development of clinically relevant AAV vectors by performing AAV library selection experiments in primate models. However, unlike the selection of AAV mutants in mice, where a large number of cell-type-specific transgenic Cre driver lines have already been established, Cre-dependent selection is not amenable in large clinically relevant animals, including non-human primates, because Cre transgenic animals are not readily available.
[0008] We therefore sought to develop a next-generation selection strategy (generation 3) with similar or better selective stringency than that provided by Cre-dependent selection, but without the need for Cre recombinase. To accomplish this goal, we developed the Transcription-dependent Directed Evolution system, or TRADE. In transcription-dependent selection, we express the AAV cap gene as a non-coding antisense mRNA driven by a cell-type specific enhancer-promoter. Recovery of this antisense transcript by RT-PCR allows for the rigorous recovery of the AAV cap gene at the level of vector-mediated mRNA expression in specific cell types without the use of Cre recombinase. Targeting of different cell types simply requires cloning different cell-type specific enhancer-promoters into the plasmid construct. Thus, TRADE is a highly flexible system that can be applied in a wide variety of contexts, including the non-human primate context, for the development of enhanced AAV vectors for clinical gene therapy. Note that the same principle can be used to express the AAV cap gene in the sense orientation. However, the sense strand approach results in expression of the immunogenic capsid protein in the target cell and is therefore not as ideal as the antisense strand approach used by the TRADE system. Summary of the Invention
[0009] This disclosure provides a method for the detection of transcription-dependent directed evolution ( TRA subscription-dependent D irected EWe provide a next-generation directed evolution strategy, named TRADE (Targeted Evolution), which selects for AAV capsid transduction at the level of cell type-specific or ubiquitous mRNA expression. The method described herein offers the following advantages over Cre recombination-based AAV targeted evolution (CREATE), the state-of-the-art method of AAV capsid directed evolution reported in the literature: Deverman et al., Nat Biotech 34, 204-209 (2016). First, the CREATE system requires Cre expression, which can be achieved either by exogenously delivered Cre expression or by the use of Cre transgenic animals. In contrast, the TRADE system does not require Cre transgenic animals, and therefore it can be applied to animals and cultured cells derived from any animal species, and can be easily adapted to large animals, including non-human primates. Second, unlike the CREATE system in which cell type-specific selection is applied at the level of AAV viral genome conversion from single-stranded DNA to double-stranded DNA, TRADE allows cell type-specific selection at the level of AAV genome transcription. Thus, the TRADE system can provide greater selection pressure than the CREATE system. Third, multiple directed evolution schemes (e.g., neuron-specific, astrocyte-specific, oligodendrocyte-specific, and microglia-specific) can be integrated into one AAV capsid library, and selection of AAV vectors targeting each cell type can be performed in one animal. Fourth, any cell type-specific or tissue / organ-specific enhancer-promoter, or ubiquitous enhancer-promoter can be easily used for AAV capsid directed evolution aimed at identifying cell type-specific or ubiquitous new AAV capsids with enhanced efficacy.Fifth, the TRADE method is not limited to the genus Dependoparvovirus, which includes the common AAVs used in gene delivery, but can be more broadly applied to the family Parvoviridae, which includes species other than AAVs (e.g., bocaviruses), such as Bocaparvoviruses and Erythroparvoviruses, and to DNA viruses more broadly.
[0010] The present disclosure further provides new AAV capsid mutants. TRADE technology was used to identify new AAV vectors that mediate neuronal transduction in the brain after intravenous administration. Application of TRADE in C57BL / 6J mice and rhesus monkeys resulted in the identification of new AAV capsids that can transduce neurons more efficiently and specifically than AAV9 in mouse and non-human primate brains after intravenous administration. In addition, we identified new AAV capsids that can transduce undefined cell populations or cell populations present in the lung and potentially of neuronal origin 5-18 times better than AAV9.
[0011] The present disclosure further provides a method for preventing splicing of antisense mRNA of AAV capsid gene. Antisense pre-mRNA transcribed from AAV cap gene open reading frame ("ORF") can (a) be spliced to create a truncated mRNA species. To our knowledge, this is a novel finding that has not been reported before. Such splicing has the potential to prevent efficient recovery of full-length antisense mRNA of AAV cap ORF, which is essential for TRADE when extensive sites of cap ORF are mutated. The present disclosure provides a new strategy for preventing splicing of antisense mRNA of cap gene.
[0012] The TRADE system described herein uses antisense mRNA to retrieve capsid sequence information, and TRADE using sense strand mRNA (i.e., sense strand TRADE) can also be performed using the same principle. However, it should be noted that the sense strand TRADE approach results in expression of immunogenic capsid proteins in target cells, and thus is presumptively less ideal than the antisense strand approach. [Brief description of the drawings]
[0013] [Figure 1]Schematic of the in vivo library selection strategy utilized for the directed evolution of AAV capsids. AAV vector-mediated transduction is a multi-step process that requires virions to overcome extracellular barriers, bind receptors on target cells, enter cells via endocytosis, escape endosomes, traffic to the nucleus, uncoat, achieve double-stranded DNA configuration, and finally undergo transcription / translation. The earliest in vivo library selection strategies (first generation) recovered all vector genomic DNA from tissue samples. In theory, this strategy would recover both effective AAV variants as well as AAV variants that mediate some, but not all, steps required for vector-mediated transgene expression. In addition, this strategy would also recover AAV vector genomic DNA from AAV vector particles that do not enter cells and remain in the extracellular matrix. Thus, screening of diverse libraries of synthetic AAV variants results in a relatively high background recovery of AAV variants that are completely ineffective gene therapy vectors. Furthermore, concentrating on specific cell types requires further processing such as fluorescence-activated cell sorting (FACS) or laser capture microdissection (LCM). The second generation of library selection (Gen2) substantially increased the selection stringency by utilizing Cre-dependent recovery of only those AAV variants capable of achieving the double-stranded DNA step of transduction. Furthermore, inducing Cre expression at a cell-type specific enhancer-promoter allows targeting of specific cell types while retaining the advantage of processing large amounts of tissue samples. The third generation of library selection (Gen3) is based on AAV directed evolution techniques by using transcription-dependent recovery of AAV variants capable of mediating transgene mRNA expression at a cell-type specific enhancer-promoter, without requiring Cre expression. [Figure 2A]Principle of TRADE. Map of AAV vector genome in TRADE construct (AAV-TRADE). A cell type specific enhancer-promoter is placed in antisense orientation to drive AAV cap gene transcript expression as antisense mRNA. A polyadenylation signal (pA) derived from the Simian Virus 40 (SV40) genome is placed within an AAV genome intron in antisense orientation to terminate antisense AAV cap gene mRNA transcription. An eGFP open reading frame (ORF) can be placed to function as a reporter or to facilitate enrichment of transduced cells by FACS, as depicted, but such a marker gene is not strictly required for TRADE. A ubiquitous promoter, such as the CAG promoter, can be placed in a cell type specific enhancer-promoter and used to identify AAV capsids capable of transducing various cell types in TRADE. A cell type specific enhancer-promoter can be placed upstream of the AAV cap gene ORF to drive expression of AAV cap gene mRNA transcript in sense orientation (i.e., sense strand TRADE). However, this approach may not be ideal for TRADE because AAV capsid proteins are expressed in the target cells, which may result in undesirable biological effects in the directed evolution process. [Figure 2B]Principle of TRADE. During AAV vector production in HEK293 cells and in the presence of adenoviral helper functions, the AAV2 viral p40 promoter induces cap gene expression (forward transcription) and cell type-specific transcripts are repressed, resulting in successful production of recombinant AAV vectors containing the AAV-TRADE vector genome. After transduction of a specific cell type, the cell type-specific enhancer-promoter is activated and induces expression of eGFP and antisense cap mRNA sequences, while the transcriptional activity of the p40 promoter remains inactive in transduced cells due to the lack of adenoviral helper functions. The entire cap gene ORF can be recovered by reverse transcription (RT)-PCR using the antisense cap gene mRNA as a template to be expressed in a cell type-specific manner. We observed that recombinant AAV vectors can be successfully produced at high levels even in the presence of antisense mRNA transcripts expressed by leaky expression from the human synapsin I gene (hSynI) enhancer-promoter in HEK293 cells. Furthermore, we observed that recombinant AAV vectors can be successfully produced at high titers even when using the CAG promoter to drive expression of antisense AAV capped mRNA transcripts at high levels. [Figure 3A] Validation of the TRADE system for targeting brain neurons. Map of the AAV-PHP.B-hSynI-GFP-TRADE vector genome. [Figure 3B]Validation of the TRADE system to target brain neurons. To demonstrate the TRADE system, the AAV vector genome was packaged into AAV-PHP.B capsids as a single-stranded DNA genome, and the resulting AAV vector was injected intravenously into two 8-week-old C57BL / 6J mice at a dose of 3×1011 vector genomes (vg) per mouse. Brain tissue was harvested 12 days after injection. Brain tissue from one animal was fixed in 4% paraformaldehyde and used for immunofluorescence microscopy, and brain tissue from the other animal was used, without fixation, for molecular analysis of AAV vector genome DNA and RNA. [Figure 3C] Validation of the TRADE system targeting brain neurons. Immunofluorescence microscopy images of brain sections stained with anti-GFP antibody confirmed cell type-specific enhancer-promoter driven transcript expression. [Figure 3D] Validation of the TRADE system targeting brain neurons. GFP expression driven by the hSynI enhancer-promoter was observed specifically in neurons (anti-HuC / D+). [Figure 3E] Validation of the TRADE system targeting brain neurons. RT-PCR was used to recover the full-length capped ORF sequence (RT+); RT-, no reverse transcriptase control; Plas, positive control obtained by DNA-PCR using a plasmid template containing the AAV-PHP.B-hSynI-GFP-TRADE vector genome sequence); NT, no template PCR control. [Figure 3F] Validation of the TRADE system targeting brain neurons. Sanger sequencing of the RT-PCR products showed the expected splicing of the MVM intron in the antisense transcript expressed by the hSynI enhancer-promoter (SEQ ID NO:190). Exon-exon junctions are highlighted in grey. [Figure 3G]Validation of the TRADE system for targeting brain neurons. Sanger sequencing confirmed insertion of the PHP.B peptide (highlighted in grey) (SEQ ID NO: 191). [Figure 4] Splicing of antisense mRNA of the AAV9 cap ORF. Two cell lines, HEK293 and Neuro2a, were transfected with a plasmid containing the AAV9 cap ORF in the TRADE configuration with or without a GFP reporter. They are shown in the figure as "GFP TRADE" and "TRADE", respectively. Cells were harvested 3 days after transfection, RNA was extracted, and RT-PCR was performed with one set of PCR primers that amplifies the complete cap ORF sequence. Instead of recovering the expected amplicon size of 2.4 kb, as shown in the positive control (PC) lane, we steadily recovered an amplicon of approximately 0.7 kb. Sanger sequencing of these RT-PCR products identified a cleavage consistent with splicing of a 1.7 kb region of the AAV9 cap ORF, shown in Figure 5. PC, positive control using a plasmid template containing the AAV-PHP.B-hSynI-GFP-TRADE vector genome sequence; NC, no template PCR control. [Diagram 5]Intron identified in antisense mRNA derived from AAV9 cap gene (SEQ ID NO:192). When the AAV-PHP.B cap gene sequence was transcribed in antisense orientation in HEK293 cells or Neuro2a cells under the control of the neuron-specific human synapsin I (hSynI) enhancer-promoter, splicing events were identified at potential splice donor and splice acceptor sites (see also FIG. 6). The underlined sequence indicates an intron found within the AAV9 cap ORF. This splicing event was not observed in mouse brain neurons. It should be noted that (1) the hSynI enhancer-promoter has been used as a neuron-specific element, but was shown to induce leaky expression in HEK293 cells; and (2) the AAV9 cap ORF sequence used in the intron splicing experiments had the following silent mutation near the C-terminus: gaaccccgccccattggcacGCgTtacCTGACTCGTAATCTGTAA (SEQ ID NO:1). Intron sequences are underlined and silent mutations introduced into the intron to create an MluI (ACGCGT) recognition site are shown in uppercase. [Figure 6]Cryptic splice donor (SD) and splice acceptor (SA) sites with shared features of exon-intron junctions are present in the antisense orientation in the AAV cap ORF. The nucleotide sequences of the cap genes derived from 122 naturally occurring AAV strains (serotypes and variants) are aligned using multiple sequence alignment programs (SEQ ID NOs: 223-316). The exon-intron junctions identified in the antisense mRNA derived from the AAV9 cap ORF are shown as solid lines. The dotted lines in the splice acceptor sites indicate putative splice acceptor sites in AAV cap ORFs that lack the splice acceptor AG / TC sequence at the predicted position of sequence conservation. The dotted lines in the splice donor regions indicate the splice donor sites identified in the antisense mRNA derived from the AAV3 cap ORF (see FIG. 7). A GT / CA splice donor site followed by a stretch of T's and an AG / TC splice acceptor motif are common features of exon-intron junctions and are highly conserved across many AAV strains. The splice donor and acceptor sites identified in the AAV9 capped ORF shown in this figure were also identified in the AAV1 capped ORF. For serotypes other than AAV1, 3, 5, and 9, the splicing events of the antisense mRNA of the AAV capped ORF are currently under investigation. The highlighted variants are common AAV serotypes. [Figure 7A]Introns identified in antisense mRNA derived from AAV3 cap gene. pAAV3-hnLSP-MCS-TRADE2 is a plasmid carrying wild-type AAV3 cap ORF placed under a liver-specific enhancer-promoter with MVM intron (hnLSP). The nucleotide sequence of AAV3 cap ORF is similar to naturally identified AAV3. HepG2 cells, a human hepatoma cell line, were transfected with plasmid pAAV3-hnLSP-MCS-TRADE2. Antisense mRNA derived from AAV3 cap ORF was then analyzed by RT-PCR. The sequences of the two truncated RT-PCR products were determined by Sanger sequencing after blunt-end TOPO cloning of the PCR products, which revealed an intron found within the antisense AAV3 cap ORF (panels A and B, SEQ ID NO:193). Intron sequences are underlined lowercase letters. The most upstream splice donor site was identified only 3 bp away from the splice donor site identified in the AAV9 capped ORF, which is indicated by a dotted line in Figure 6. The most downstream splice acceptor site is found approximately 80 bp upstream of the AAV9 capped ORF. Note that all splice donor and acceptor sites identified in the AAV3 capped ORF were also identified in the AAV1 capped ORF. [Figure 7B]Introns identified in antisense mRNA derived from AAV3 cap gene. pAAV3-hnLSP-MCS-TRADE2 is a plasmid carrying wild-type AAV3 cap ORF placed under a liver-specific enhancer-promoter with MVM intron (hnLSP). The nucleotide sequence of AAV3 cap ORF is similar to naturally identified AAV3. HepG2 cells, a human hepatoma cell line, were transfected with plasmid pAAV3-hnLSP-MCS-TRADE2. Antisense mRNA derived from AAV3 cap ORF was then analyzed by RT-PCR. The sequences of the two truncated RT-PCR products were determined by Sanger sequencing after blunt-end TOPO cloning of the PCR products, which revealed an intron found within the antisense AAV3 cap ORF (panels A and B, SEQ ID NO:193). Intron sequences are underlined lowercase letters. The most upstream splice donor site was identified only 3 bp away from the splice donor site identified in the AAV9 capped ORF, which is indicated by a dotted line in Figure 6. The most downstream splice acceptor site is found approximately 80 bp upstream of the AAV9 capped ORF. Note that all splice donor and acceptor sites identified in the AAV3 capped ORF were also identified in the AAV1 capped ORF. [Figure 8A]Additional cryptic splice acceptor sites exist in the AAV cap ORF. The nucleotide sequences of the cap genes from 122 naturally occurring AAV strains (serotypes and variants) are aligned using multiple sequence alignment programs (SEQ ID NOs: 317-420). The exon-intron junction of the splice acceptor site identified in the antisense mRNA derived from the AAV9 cap ORF is shown as a solid line. The dotted line in panel A indicates an alternative putative splice acceptor site near the experimentally determined splice acceptor site. An AG / TC splice acceptor site followed by a stretch of T's is a common feature of exon-intron junctions of splice acceptor sites and is highly conserved across many AAV strains. The AAV3 cap ORF is highlighted. The splice acceptor site identified in the AAV3 cap ORF shown in panels A and B has also been identified in the AAV1 cap ORF. For the AAV5 cap ORF, no splicing events have been observed at either site of the antisense mRNA transcript. For serotypes other than AAV1, 3, 5, and 9, splicing events of the antisense mRNAs of the AAV cap ORF are currently under investigation. [Figure 8B]Additional cryptic splice acceptor sites exist in the AAV cap ORF. The nucleotide sequences of the cap genes from 122 naturally occurring AAV strains (serotypes and variants) are aligned using multiple sequence alignment programs (SEQ ID NOs: 317-420). The exon-intron junction of the splice acceptor site identified in the antisense mRNA derived from the AAV9 cap ORF is shown as a solid line. The dotted line in panel A indicates an alternative putative splice acceptor site near the experimentally determined splice acceptor site. An AG / TC splice acceptor site followed by a stretch of T's is a common feature of exon-intron junctions of splice acceptor sites and is highly conserved across many AAV strains. The AAV3 cap ORF is highlighted. The splice acceptor site identified in the AAV3 cap ORF shown in panels A and B has also been identified in the AAV1 cap ORF. For the AAV5 cap ORF, no splicing events have been observed at either site of the antisense mRNA transcript. For serotypes other than AAV1, 3, 5, and 9, splicing events of the antisense mRNAs of the AAV cap ORF are currently under investigation. [Figure 9] Additional potential splice donor sites present in the AAV cap ORF. The nucleotide sequences of the cap genes from 122 naturally occurring AAV strains (serotypes and variants) are aligned using multiple sequence alignment programs (SEQ ID NOs: 421-461). The exon-intron junction of the splice donor site identified in the antisense mRNA derived from the AAV3 cap ORF is indicated by a solid line. The GT / CA splice donor consensus sequence at this position is retained by only half of the AAV strains. This splice donor site was identified in the AAV1 cap ORF. [Figure 10]Splice donor and splice acceptor sites identified in the AAV1 cap ORF. The nucleotide sequence of the AAV1 cap ORF is shown (SEQ ID NO:194). The AAV1 cap ORF was expressed by the hSynI enhancer-promoter in human embryonic kidney (HEK) 293 cells or Neuro2a cells in the antisense orientation. The antisense mRNA derived from the AAV1 cap ORF was then analyzed by RT-PCR. The sequence of the RT-PCR product was determined by Sanger sequencing after blunt-end TOPO cloning of the PCR product, which revealed an intron found within the AAV1 cap ORF. The exon-intron junctions identified in the antisense AAV1 cap mRNA are indicated with AG / TC for the splice donor site and GT / CA for the splice acceptor site. The capitalized AG / TC and GT / CA are the consensus dinucleotides at the 5' and 3' ends of the intron, respectively. Since splicing occurs in the antisense mRNA of the ORF, the intron sequences are various combinations of the above sequences between CT (splice acceptor) and AC (splice donor). Detailed information on the observed splice donor and acceptor combinations is not shown. The two conserved nucleotides of the exon-intron junction (CT or AC) shown in bold are those that are highly conserved across various AAV serotypes. The two conserved nucleotides of the exon-intron junction (CT or AC) that are underlined are those that were identified in the antisense AAV3 or AAV9 capped mRNA transcripts. [Figure 11]Splicing-suppressing mutagenesis of the AAV9 capped ORF. Silent mutations are introduced around the splice acceptor (SA) and / or splice donor (SD) sites of the AAV9 capped ORF to suppress splicing observed on the antisense mRNA transcript. The spliced introns of the native sequences (SEQ ID NO:195, SEQ ID NO:196) are underlined. The AAV9NS1 genome (SEQ ID NO:197) has one set of mutations around the SA site, while the AAV9NS2 genome (SEQ ID NO:198) has one set of mutations around the SD site. The AAV9NS3 genome has both sets of mutations. The numbers to the right indicate the nucleotide position relative to the first nucleotide of the AAV9 capped ORF. [Figure 12] Mutations introduced around the splice donor and / or acceptor sites effectively suppress splicing of antisense mRNA derived from the AAV9 capped ORF. Neuro2a cells were transfected with plasmids containing the AAV9 capped ORF and various potentially splicing-suppressing mutations (NS1-3) in the TRADE construct. RNA was harvested 3 days after transfection and RT-PCR was performed with one set of PCR primers capable of recovering the entire capped ORF sequence. In stark contrast to the results seen in Figure 4, full-length amplicons were successfully recovered. NS1, AAV9-TRADE vector genome with codon-modified splice acceptor. NS2, AAV9-TRADE vector genome with codon-modified splice donor. NS3, AAV9-TRADE vector genome with codon-modified splice acceptor and splice donor. PC, positive control using a plasmid template containing the AAV-PHP.B-hSynI-GFP-TRADE vector genome sequence; NC, no template PCR control. [Figure 13A]Study design for application of TRADE to identify enhanced AAV variants for brain neuron transduction following systemic AAV vector injection. Map of AAV9-N272A-hSynI-GFP-TRADE-PepLib vector genome. The hSynI enhancer-promoter is utilized to drive expression specifically in neurons. Liver-detargeted AAV9-N272A cap (PCT / US2017 / 068050) serves as a platform for AAV library generation. A random eight amino acid peptide, encoded by (NNK)8 and flanked by a glycine-serine linker (SEQ ID NO:2), was substituted for Q588 of the AAV9-N272A cap sequence (SEQ ID NO:222). [Figure 13B] Study design for application of TRADE to identify enhanced AAV variants for brain neuron transduction following systemic AAV vector injection. Plasmid libraries were used to generate AAV libraries using a triple transfection protocol. The libraries were purified through PEG precipitation and two rounds of CsCl ultracentrifugation and then injected via the tail vein at a dose of 3 x 1011 vg / mouse. Brain tissue was harvested 12 days after injection. RNA was recovered using TRIzol, and RT-PCR was used to recover cap fragments containing the peptide insert, which were then recloned into the AAV vector plasmid backbone. This was repeated for three rounds of selection in C57BL / 6J mice. In parallel, one selection was performed in rhesus monkeys using a dose of 2.7 x 1012 vg / kg. [Figure 14A]Validation of neuronal transduction of 26 new AAV capsids by AAV RNA barcode-sequences in mice and non-human primates. Map of double-stranded (ds) AAV-hSynI-GFP-BC vector. A pair of two 12-nucleotide long DNA barcodes (VBCx-L and VBCx-R) are placed under the human synapsin I (hSynI) gene enhancer-promoter. These two viral barcodes (VBCs) can be expressed as transcripts specifically in cells (i.e., neurons) where the hSynI enhancer-promoter is active. [Figure 14B] Validation of neuronal transduction of 26 novel AAV capsids by AAV RNA barcode-sequencing in mice and non-human primates. Neuronal transduction of 26 novel AAV variants, HN1-HN26 (five variants identified in mice and 21 variants identified in non-human primates), identified by TRADE, and three control AAV capsids (AAV9, AAV9-N272A, and AAV-PHP.B) in C57BL / 6J and BALB / cJ mice. A DNA / RNA barcoded dsAAV-hSynI-GFP-BC library (dsAAV-hSynI-GFP-BCLib) containing 26 new AAV variants identified by TRADE (5 variants identified by TRADE in mice and 21 variants identified by TRADE in non-human primates) and control AAV capsids (AAV9, AAV9-N272A, and AAV-PHP.B) was intravenously injected into three adult male C57BL / 6J mice and three adult male BALBcJ mice at a dose of 5 × 10 vg per mouse. Two weeks after injection, various tissues were harvested and transduction was analyzed at the AAV vector genome transcript level by AAV RNA barcode-seq. Transduction levels are expressed as phenotypic difference (PD) values relative to the reference control, AAV9. For AAV capsid amino acid sequence information of HN1-HN26 variants, see Table 3. [Figure 14C]Validation of neuronal transduction of 26 new AAV capsids by AAV RNA barcode-seq in mice and non-human primates. Neuronal transduction of 26 new AAV variants, and three control AAV capsids, in the hippocampus of rhesus macaques. The same DNA / RNA barcoded AAV library was injected intravenously into one young male rhesus macaque at a dose of 2x1013vg / kg. Two weeks after injection, different brain regions were harvested and transduction was analyzed by AAV RNA barcode-seq. [Figure 14D] Validation of neuronal transduction of 26 new AAV capsids by AAV RNA barcode-seq in mice and non-human primates. The relative neuronal transduction efficiency of three TRADE variants, HN1, HN2 and HN3 and AAV-PHP.B, was analyzed by AAV RNA barcode-seq in 12 different brain regions of one rhesus macaque used for panel C. In panels B, C and D, the dotted line indicates the PD value of AAV9 (i.e., 1.0). [Figure 15A] Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification. We produced AAV9, AAV-PHP.B and AAV9-N272A-HN1 vectors containing self-complementary AAV genomes expressing eGFP under the control of the hSynI enhancer-promoter (dsAAV-hSynI-eGFP). Purified vectors were administered via the tail vein into 8-week-old male C57BL / 6J or BALB / cJ mice (n=4 mice / vector / mouse strain) at a dose of 3×1011vg / mouse. Three weeks after injection, mice were perfused transcardially with 4% paraformaldehyde and brain tissue was processed for immunohistochemistry. Map of the self-complementary hSynI-eGFP vector genome. [Figure 15B]Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification. We produced AAV9, AAV-PHP.B and AAV9-N272A-HN1 vectors containing self-complementary AAV genomes expressing eGFP under the control of the hSynI enhancer-promoter (dsAAV-hSynI-eGFP). Purified vectors were administered via the tail vein into 8-week-old male C57BL / 6J or BALB / cJ mice (n=4 mice / vector / mouse strain) at a dose of 3×1011vg / mouse. Three weeks after injection, mice were perfused transcardially with 4% paraformaldehyde, and brain tissue was processed for immunohistochemistry. Representative tile-scan images of sagittal sections stained with anti-GFP antibody. [Figure 15C] Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification. We produced AAV9, AAV-PHP.B and AAV9-N272A-HN1 vectors containing self-complementary AAV genomes expressing eGFP under the control of the hSynI enhancer-promoter (dsAAV-hSynI-eGFP). Purified vectors were administered via the tail vein into 8-week-old male C57BL / 6J or BALB / cJ mice (n=4 mice / vector / mouse strain) at a dose of 3×1011vg / mouse. Three weeks after injection, mice were perfused transcardially with 4% paraformaldehyde, and brain tissue was processed for immunohistochemistry. (B) Quantification of neuronal transduction based on automated counting of cells expressing eGFP and NeuN in four brain regions. [Figure 15D]Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification. We produced AAV9, AAV-PHP.B and AAV9-N272A-HN1 vectors containing self-complementary AAV genomes expressing eGFP under the control of the hSynI enhancer-promoter (dsAAV-hSynI-eGFP). Purified vectors were administered via the tail vein into 8-week-old male C57BL / 6J or BALB / cJ mice (n=4 mice / vector / mouse strain) at a dose of 3×1011vg / mouse. Three weeks after injection, mice were perfused transcardially with 4% paraformaldehyde, and brain tissue was processed for immunohistochemistry. Validation of the automated computational process in (B) and (C). Representative 20X confocal images of the visual cortex are shown. Scale bars are 100 μm. [Figure 15E] Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification. We produced AAV9, AAV-PHP.B and AAV9-N272A-HN1 vectors containing self-complementary AAV genomes expressing eGFP under the control of the hSynI enhancer-promoter (dsAAV-hSynI-eGFP). Purified vectors were administered via the tail vein into 8-week-old male C57BL / 6J or BALB / cJ mice (n=4 mice / vector / mouse strain) at a dose of 3×1011vg / mouse. Three weeks after injection, mice were perfused transcardially with 4% paraformaldehyde and brain tissue was processed for immunohistochemistry. (D) Quantification of neuronal transduction based on manual counting by a blinded observer of cells expressing eGFP and NeuN. Error bars indicate + / - standard error of the mean (SEM) ***p<0.001. [Figure 16A]Validation of AAV9-N272A-HN1 transduction enhanced against AAV9 in rhesus macaques using epitope-tagged eGFP reporter vectors. AAV-CAG-nlsGFP vectors used in this study. We produced four AAV vectors: AAV9-CAG-FLAGnlsGFP-BCLib, AAV9-CAG-HAnlsGFP-BCLib, AAV9-N272A-HN1-CAG-FLAGnlsGFP-BCLib, and AAV9-N272A-HN1-CAG-HAnlsGFP-BCLib. nlsGFP (eGFP with a nuclear localization signal derived from the SV40 large T antigen) was tagged with either a FLAG tag or an HA tag at the N-terminus. Each vector was a DNA / RNA barcoded library containing an approximately 1:1 mixture of nine various DNA / RNA barcoded viral clones, although this feature was not used in this study. The two vectors in the top half depicted in panel A were mixed in a 1:1 ratio to make AAV Library 1 (AAVLib1), and the two vectors in the bottom half were mixed in a 1:1 ratio to make AAV Library 2 (AAVLib2). In this experimental scheme, AAVLib1 and AAVLib2 each contain AAV9 and AAV9-N272A-HN1 vectors expressing epitope-tagged nlsGFP in a 1:1 ratio, but the capsid-epitope relationship is inverted to avoid potential antibody bias in downstream mass spectrometry analysis. [Figure 16B]Validation of transduction of AAV9-N272A-HN1 enhanced against AAV9 in rhesus macaques using epitope-tagged eGFP reporter vector. Representative tile-scanned brain cross-sections from one animal receiving AAVLib. Each AAV library was administered intravenously to young rhesus macaques at a dose of 3x1013vg / kg. Tissues were harvested 3 weeks post-injection, cut into 4 mm slabs, fixed in 4% paraformaldehyde, and processed with anti-GFP, anti-FLAG, and anti-HA antibodies for immunohistochemistry. eGFP expression indicates that cells were transduced by either AAV9 or AAV9-N272A-HN1, or both. FLAG staining indicates that AAV9 capsid mediated transduction, while HA staining indicates that AAV9-N272A-HN1 mediated transduction. Top right inset, motor cortex; bottom right inset, putamen. This experiment revealed that AAV9-N272A-HN1 transduced brain cells several times better than AAV9 with strong neurotropism compared to AAV9. Therefore, as far as neuronal transduction is concerned, AAV9-N272A-HN1 mediated much higher neuronal transduction than AAV9. [Figure 17A]Biodistribution of AAV9-N272A-HN1 to major peripheral organs after systemic delivery in mice and rhesus monkeys. We used AAV DNA barcode-sequence to determine the relative abundance of AAV vector genomic DNA in each peripheral organ delivered by each AAV capsid contained in the dsAAV-hSynI-GFP-BCLib library (panels A, B, and C). As explained above, the dsAAV-hSynI-GFP-BCLib library contained 26 AAV variants identified by TRADE in mice and non-human primates, along with control, AAV9, AAV9-N272A, and AAV-PHP.B. DNA was extracted from various tissues after administration of the dsAAV-hSynI-GFP-BCLib library (see Table 3) and subjected to AAV DNA barcode-sequence analysis. Additionally, we used AAV RNA barcode-sequences to determine the relative transduction efficiency compared to AAV9 in each peripheral organ of rhesus macaques injected intravenously with the ssAAV-CAG-nlsGFP-BCLib library depicted in Figure 16A (panel D). Biodistribution of AAV9, AAV9-N272A, AAV-PHP.B and TRADE mutants to liver in C57BL / 6J mice, BALB / cJ mice and rhesus macaques for AAV9. [Figure 17B]Biodistribution of AAV9-N272A-HN1 to major peripheral organs after systemic delivery in mice and rhesus monkeys. We used AAV DNA barcode-sequence to determine the relative abundance of AAV vector genomic DNA in each peripheral organ delivered by each AAV capsid contained in the dsAAV-hSynI-GFP-BCLib library (panels A, B, and C). As explained above, the dsAAV-hSynI-GFP-BCLib library contained 26 AAV variants identified by TRADE in mice and non-human primates, along with control, AAV9, AAV9-N272A, and AAV-PHP.B. DNA was extracted from various tissues after administration of the dsAAV-hSynI-GFP-BCLib library (see Table 3) and subjected to AAV DNA barcode-sequence analysis. Additionally, we used AAV RNA barcode-sequences to determine the relative transduction efficiency compared to AAV9 in each peripheral organ of rhesus macaques intravenously injected with the ssAAV-CAG-nlsGFP-BCLib library depicted in Figure 16A (panel D). Biodistribution of AAV9-N272A-HN1 to major peripheral organs other than liver in C57BL / 6J and BALB / cJ mice (n=3 mice / strain). [Figure 17C]Biodistribution of AAV9-N272A-HN1 to major peripheral organs after systemic delivery in mice and rhesus monkeys. We used AAV DNA barcode-sequence to determine the relative abundance of AAV vector genomic DNA in each peripheral organ delivered by each AAV capsid contained in the dsAAV-hSynI-GFP-BCLib library (panels A, B, and C). As explained above, the dsAAV-hSynI-GFP-BCLib library contained 26 AAV variants identified by TRADE in mice and non-human primates, along with control, AAV9, AAV9-N272A, and AAV-PHP.B. DNA was extracted from various tissues after administration of the dsAAV-hSynI-GFP-BCLib library (see Table 3) and subjected to AAV DNA barcode-sequence analysis. Additionally, we used AAV RNA barcode-sequences to determine the relative transduction efficiency compared to AAV9 in each peripheral organ of a rhesus macaque injected intravenously with the ssAAV-CAG-nlsGFP-BCLib library depicted in Figure 16A (panel D). Biodistribution of AAV9-N272A-HN1 to major peripheral organs other than liver in rhesus macaques (n=1) based on dsAAV-hSynI-GFP-BC analysis. For this experiment, AAV DNA barcode-sequence analysis was performed on samples collected from one rhesus macaque injected with the dsAAV-hSynI-GFP-BCLib library shown in Figure 14D. [Figure 17D]Biodistribution of AAV9-N272A-HN1 to major peripheral organs after systemic delivery in mice and rhesus monkeys. We used AAV DNA barcode-sequence to determine the relative abundance of AAV vector genomic DNA in each peripheral organ delivered by each AAV capsid contained in the dsAAV-hSynI-GFP-BCLib library (panels A, B, and C). As explained above, the dsAAV-hSynI-GFP-BCLib library contained 26 AAV variants identified by TRADE in mice and non-human primates, along with control, AAV9, AAV9-N272A, and AAV-PHP.B. DNA was extracted from various tissues after administration of the dsAAV-hSynI-GFP-BCLib library (see Table 3) and subjected to AAV DNA barcode-sequence analysis. In addition, we used AAV RNA barcode-sequences to determine the relative transduction efficiency compared to AAV9 in each peripheral organ of rhesus macaques injected intravenously with the ssAAV-CAG-nlsGFP-BCLib library depicted in Figure 16A (panel D). Biodistribution of AAV9-N272A-HN1 to major peripheral organs other than liver in rhesus macaques (n=2) based on ssAAV-CAG-nlsGFP-BC analysis. For this experiment, AAV RNA barcode-sequence analysis was performed on samples collected from rhesus macaques injected with the ssAAV-GAG-nlsGFP-BCLib vector shown in Figure 16A. Error bars indicate + / - standard error of the mean (SEM). AAV9-N272A-HN1 capsids transduced peripheral organs to a lower extent compared to AAV9 capsids. [Figure 18A]AAV9-N272A-HN1 has a high degree of neurotropism after systemic administration in mice. AAV9 and AAV9-N272A-HN1 vectors expressing nlsGFP under the control of the strong ubiquitous CAG promoter were injected intravenously into 8-week-old male BALB / cJ mice at a dose of 3 x 1011 vg / mouse. Tissues were harvested 12 days post-injection and analyzed by immunostaining with anti-GFP and anti-NeuN antibodies. Map of the single-stranded (ss) AAV-CAG-nlsGFP vector genome used in this study. [Figure 18B] AAV9-N272A-HN1 has a high degree of neurotropism after systemic administration in mice. AAV9 and AAV9-N272A-HN1 vectors expressing nlsGFP under the control of the strong ubiquitous CAG promoter were injected intravenously into 8-week-old male BALB / cJ mice at a dose of 3 × 1011 vg / mouse. Tissues were harvested 12 days after injection and analyzed by immunostaining with anti-GFP and anti-NeuN antibodies. Representative images of mouse cerebral cortex transduced with AAV9-N272A-HN1-CAG-nlsGFP. Moreover, the vast majority of cells transduced with AAV9-N272A-HN1-CAG-nlsGFP are also positive for the neuronal marker NeuN. Scale bar is 100 μm. [Figure 18C] AAV9-N272A-HN1 has a high degree of neurotropism after systemic administration in mice. AAV9 and AAV9-N272A-HN1 vectors expressing nlsGFP under the control of a strong ubiquitous CAG promoter were injected intravenously into 8-week-old male BALB / cJ mice at a dose of 3 × 1011 vg / mouse. Tissues were harvested 12 days after injection and analyzed by immunostaining with anti-GFP and anti-NeuN antibodies. Neuronal specificity of AAV9 and AAV9-N272A-HN1 capsids. Quantification of neuronal specificity was determined by dividing the number of double-positive cells (eGFP+ / NeuN+) by the total number of GFP+ cells. AAV9-N272A-HN1 is highly specific for neurons (96%) compared to AAV9 (56%). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] In some embodiments, the present disclosure provides a TRADE system, which allows for the directed evolution of AAV capsids using antisense mRNA of the cap ORF expressed in a cell type-specific or ubiquitous manner. Such a system does not require Cre transgenic animals. Thus, it can be applied to cell type-specific AAV capsid evolution in large animals, including non-human primates, where Cre transgenic strains are not readily available. Any cell type-specific or tissue / organ-specific enhancer-promoter or ubiquitous enhancer-promoter can be easily applied to the system without the need for transformation. Cell type-specific selection is given at the mRNA level. In certain embodiments, multiple directed evolution schemes may be combined into one directed evolution scheme. For example, selection of neuron-specific AAV capsids, astrocyte-specific AAV capsids, oligodendrocyte-specific AAV capsids and microglia-specific AAV capsids based on cell type-specific transgene mRNA expression can be performed simultaneously in one animal.
[0015] In some embodiments, the present disclosure provides a sense strand TRADE system, which allows the directed evolution of AAV capsids using the mRNA of the cap ORF expressed in a cell type-specific or ubiquitous manner that can express the AAV capsid protein in the target cell. Sense strand TRADE has the same advantages of the antisense strand TRADE presented in the data here, which are that it does not require Cre transgenic animals, cell type-specific selection is given at the mRNA level, and multiple directed evolution schemes can be combined into one directed evolution performed in one animal. However, the possible disadvantage is that the immunogenic AAV capsid protein may be unavoidably expressed persistently in the target cell, which may result in an undesirable outcome of the capsid selection process.
[0016] In some embodiments, the present disclosure further provides new AAV capsids. In some embodiments, these new AAV capsids can transduce brain neurons many times better than AAV9 in C57BL / 6J mice after intravenous injection. In some embodiments, the new AAV capsids transduced up to 8 times better than AAV9 in C57BL / 6J mice after intravenous injection. Neuron transduction levels may be greatly enhanced compared to AAV9, even if they do not reach the levels obtained with AAV PHP.B. In some embodiments, the new AAV capsids may transduce brain neurons more efficiently than AAV PHP.B.
[0017] In some embodiments, the present disclosure provides a new AAV capsid that can transduce brain neurons in BALB / cJ mice many times better than AAV9 after intravenous injection. In some embodiments, the new AAV capsid can transduce brain neurons in BALB / cJ mice up to 7 times better than AAV9 after intravenous injection. The transduction level is much higher than AAV PHP.B.
[0018] In some embodiments, the present disclosure provides a new AAV capsid that can transduce brain neurons many times better than AAV9 in rhesus monkeys after intravenous injection. In some embodiments, the new AAV capsid can transduce brain neurons up to four times better than AAV9 in rhesus monkeys after intravenous injection. These transduction levels are better than AAV PHP.B.
[0019] In some embodiments, the present disclosure provides AAV capsids that can transduce lung cells with neuronal cell marker expression several fold better than AAV9, in certain embodiments, the AAV capsids can transduce such cells up to 17 fold better than AAV9.
[0020] In some embodiments, the new AAV capsid exhibits a liver detargeting phenotype.
[0021] In some embodiments, the present disclosure provides codon-modified AAV cap sequences that are not spliced when expressed in the antisense direction. We have observed that unmodified AAV cap ORFs are spliced when expressed in the antisense direction (e.g., AAV1, AAV3 and AAV9). In contrast, some of the codon-modified AAV cap ORFs described in the present disclosure are not spliced. Based on our developed knowledge of putative splice donor and acceptor sites, it has become possible to design such unspliced AAV cap ORF versions. The use of such unspliced cap ORFs may be used for directed evolution using the TRADE system when mutagenesis of the cap gene occurs over a broad region of the cap ORF.
[0022] The term "AAV vector" as used herein means any vector that contains or is derived from components of AAV and is suitable for infecting mammalian cells, including human cells, in any of a number of tissue types, such as brain, heart, lung, skeletal muscle, liver, kidney, spleen or pancreas in vitro or in vivo. The term "AAV vector" may also be used to refer to an AAV-type viral particle (or virion) that contains at least a nucleic acid molecule encoding a protein of interest.
[0023] Furthermore, the AAV disclosed herein may be derived from various serotypes, including combinations of serotypes (e.g., "pseudotype" AAV), or various genomes (e.g., single-stranded or self-correcting). In certain embodiments, the AAV vectors disclosed herein may contain a desired protein or protein variant. "Variants" as used herein refer to an amino acid sequence that is altered by one or more amino acids. A variant may have "conservative" changes, such as replacing leucine with isoleucine, where the substituted amino acids have similar structural or chemical properties. Alternatively, a variant may have "non-conservative" changes, such as replacing glycine with tryptophan. Similar minor changes may also include amino acid deletions or insertions, or both.
[0024] Nucleotide sequences, such as polynucleotides, that code for the proteins of the present disclosure are provided herein.The nucleotides of the present disclosure can be either RNA or DNA.The present disclosure further encompasses polynucleotides that are complementary in sequence to the polynucleotides disclosed herein.
[0025] Due to the degeneracy of genetic code, a variety of different polynucleotide sequences can code for the protein of the present disclosure.In addition, it is within the skill of a person trained in the art to create alternative polynucleotide sequences that code for the protein similar to or essentially similar to the protein disclosed herein.These variants or alternative polynucleotide sequences are within the scope of the present disclosure.As used herein, the reference to "essentially similar sequence" refers to one or more sequences that code for amino acid substitutions, deletions, additions or insertions that do not eliminate the detectability of the polypeptide encoded by the polynucleotide of the present disclosure.
[0026] The present disclosure further includes variants of the polynucleotides and polypeptides disclosed herein. Variant sequences include those in which one or more peptides or nucleotides of the sequences have been substituted, deleted, and / or inserted.
[0027] The polynucleotide and polypeptide sequences of the present disclosure may be defined in terms of a particular identity and / or similarity to the polynucleotides and polypeptides described herein. Sequence identity is typically greater than 60%, preferably greater than 75%, more preferably greater than 80%, even more preferably greater than 90%, and may be greater than 95%. Sequence identity and / or similarity can be 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical compared to the sequences disclosed herein. Unless otherwise specified, as used herein, the percent sequence identity and / or similarity of two sequences may be determined using the algorithm of Karlin and Altschul (1990), as modified by Karlin and Altschul (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (1990). BLAST searches may be performed with the NBLAST program, score=100, wordlength=12, to obtain sequences having a desired percent sequence identity. To obtain gapped alignments for comparison purposes, Gapped BLAST may be used as described in Altschul et al. (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (NBLAST and XBLAST) may be used.
[0028] Methods for producing AAV vectors as disclosed herein are known in the art, including, for example, the use of packaging cells, auxiliary viruses or plasmids, and / or baculovirus systems.See, for example, Samulski et al., J. Virology 63, 3822 (1989); Xiao et al., J. Virology 72, 2224 (1998); Inoue et al., J. Virology 72, 7024 (1998); WO1998 / 022607; and WO2005 / 072364.In some embodiments, AAV vectors can be prepared or derived from various serotypes of AAV, which can be mixed together or mixed with other types of viruses to produce chimeric (e.g., pseudotyped) AAV viruses.
[0029] Various modifications or formulations of AAV vectors are also known (see, e.g., WO01 / 23001; WO00 / 73316; WO04 / 112727; WO05 / 005610; also see WO99 / 06562), along with methods for producing pseudotyped AAV vectors to reduce their immunogenicity upon in vivo administration (see, e.g., WO00 / 28004). In some embodiments, AAV vectors may be prepared or derived from various serotypes of AAV, which may be mixed together or mixed with other types of viruses to produce chimeric (e.g., pseudotyped) AAV viruses.
[0030] In certain embodiments, the AAV vector may be a human serotype AAV vector.In such embodiments, the human AAV may be derived from any known serotype, for example, any one of serotypes 1-11, for example, AAV1, AAV2, AAV4, AAV6, or AAV9.
[0031] The AAV vectors disclosed herein may include a nucleic acid encoding a protein of interest. In various embodiments, the nucleic acid may further include one or more control sequences that allow for expression, and in some embodiments, secretion, of the protein of interest, such as, for example, a promoter, an enhancer, a polyadenylation signal, an internal ribosome entry site ("IRES"), a sequence encoding a protein transduction domain ("PTD"), a 2A peptide, and the like. Thus, in some embodiments, the nucleic acid may include a promoter region operably linked to the coding sequence to cause or improve expression of the protein of interest in infected cells. Such promoters may be ubiquitous, cell or tissue specific, strong, weak, regulated, chimeric, and the like, for example, to allow efficient and stable production of the protein in infected tissues. Generally, promoters used in the disclosed methods are functional in human cells, although the promoter may be homologous or heterologous to the encoded protein. Examples of regulated promoters include, but are not limited to, tet on / off element-containing promoters, rapamycin-inducible promoters, tamoxifen-inducible promoters, and metallothionein promoters. Other promoters that may be used include tissue-specific promoters for tissues such as kidney, spleen and pancreas. Examples of ubiquitous promoters include viral promoters, particularly the CMV promoter, the RSV promoter, the SV40 promoter, and cellular promoters such as the phosphoglycerate kinase (PGK) promoter and the β-actin promoter.
[0032] In some embodiments of the AAV vector disclosed herein, one or more feedback elements may be used to attenuate overexpression of a protein of interest.For example, some embodiments of the AAV vector may include one or more siRNA sequences that target exogenous transcripts.In other embodiments, the AAV vector may include one or more additional promoters that can be recognized by repressive transcription factors.In various embodiments, the AAV vector disclosed herein may include a construct that can create a homeostatic feedback loop that can maintain the expression level of a protein of interest at physiological levels.
[0033] In some embodiments of the AAV vectors disclosed herein, genome editing mechanisms may be used to genetically modify cellular genomic DNA or mRNA transcripts in a site-specific manner. Komor et al., Cell 168, 20-36 (2017); and Katrekar et al., Nature Methods 16:239-242, 2019. For example, some embodiments of the AAV vector may include CRISPR-associated enzymes, such as Cas9, DNA base editors, RNA editases, and / or guide RNAs (gRNAs), to modify cellular nucleic acids in a site-specific manner. Additionally, the AAV vector may include a homology-directed repair template (HDR) for genome editing.
[0034] In various embodiments, the AAV vectors disclosed herein may contain nucleic acids that may contain a leader sequence that allows for the secretion of the encoded protein. In some embodiments, fusion of the transgene of interest with a sequence that codes for a secretory signal peptide (usually located at the N-terminus of the secreted polypeptide) may allow for the production of a therapeutic protein in a form that can be secreted from the transduced cell. Examples of such signal peptides include albumin, β-glucuronidase, alkaline protease, or fibronectin secretory signal peptides.
[0035] As described herein, efficient and long-term expression of therapeutic proteins of interest in the brain, heart, lungs, skeletal muscle, kidneys, spleen, or pancreas can be achieved using non-invasive techniques through peripheral administration of certain AAV vectors, such as non-AAV9 vectors with AAV9 sequences. Such peripheral administration may include any route of administration that does not require direct injection into the brain, heart, lungs, skeletal muscle, kidneys, spleen, or pancreas. More specifically, peripheral administration may include systemic injection, such as intramuscular injection, intravascular (such as intravenous) injection, intraperitoneal injection, intraarterial injection, or subcutaneous injection. In some embodiments, peripheral administration may further include oral administration (see, e.g., WO96 / 40954), delivery using an implant (see, e.g., WO01 / 91803), or administration by instillation through the respiratory system, e.g., using a spray, aerosol, or other suitable formulation.
[0036] In various embodiments, the desired dosage of the AAV vector may be adapted by one skilled in the art depending on, for example, the disease state, the subject, the treatment schedule, etc. In some embodiments, the dosage is 10 5 ~10 12 of viral genomes, e.g., 10 6 ~10 11 , 10 7 ~10 11 , 10 8 ~10 11 In other embodiments, an exemplary dosage to achieve a therapeutic effect is at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , or 10 11 It may include the viral titer of the viral genome. The viral titer may be expressed in terms of transducing units, which may be readily calculated by one of skill in the art.
[0037] In various embodiments, the AAV vectors disclosed herein may be administered in any suitable form, for example, as either a liquid solution or suspension, as a solid form suitable for dissolution or suspension in liquid prior to injection, as a gel, or as an emulsion. The vector may be formulated with any suitable pharma- ceutically acceptable excipient, carrier, adjuvant, diluent, etc. For example, for injection, a suitable carrier or diluent may be an isotonic solution, a buffer, sterile and pyrogen-free water, or, for example, sterile and pyrogen-free phosphate buffered saline. For inhalants, the carrier may be in the form of microparticles.
[0038] A vector may be administered in a "therapeutically effective" amount, e.g., an amount sufficient to alleviate (e.g., reduce, diminish) at least one symptom associated with a disease state or provide an improvement in the subject's condition. In some embodiments, repeated administrations may be performed, e.g., using the same or different peripheral administration routes and / or the same vector or distinct vectors. EXAMPLES
[0039] The following examples are for illustrative purposes only: in light of the present disclosure, one of ordinary skill in the art will recognize that variations of these examples, and other embodiments of the disclosed subject matter, are possible without undue experimentation.
[0040] To identify novel AAV capsids that efficiently transduce brain neurons after systemic delivery, we applied the TRADE system to both C57BL / 6J mice and rhesus macaques. The TRADE system utilizes a plasmid construct that contains an overlapping, bicistronic AAV genome flanked by ITR sequences (Figure 2A). In the sense orientation, the AAV2 p40 promoter drives expression of the AAV cap gene to promote efficient production of viral particles (Figure 2B). In the antisense orientation, a cell type-specific enhancer promoter (e.g., the human synapsis I (hSynI) enhancer promoter) drives expression of a transcript encoding GFP and an antisense cap sequence that terminates with a polyadenylation signal (polyA) embedded in an intron present in the AAV2 genome (Figure 2B). An AAV library was generated based on the liver-detargeted AAV9-N272A (PCT / US2017 / 068050) capped gene platform, which utilizes the TRADE construct as a cloning backbone and contains a random 8-mer peptide substituted at position Q588 of the AAV9 capsid with a glycine-serine linker (5'-GGGS; 3'-GGGGS). In vivo selection in specific cell types (such as neurons) was performed by retrieving capsid sequences as antisense capped ORF mRNA from brain tissue by RT-PCR. This method ensures that the retrieved sequences are only derived from AAV variants that are capable of mediating RNA expression in infected cells of interest. When the hSynI enhancer promoter is used, only sequences of the AAV capsid that are capable of transducing neurons are retrieved, thus allowing neuron-specific selection of AAV capsids.
[0041] First, we tested the ability of the TRADE system to recover AAV cap gene sequences from cell type-specific antisense mRNA using the AAV-PHP.B-hSynI-GFP-TRADE vector (Figure 3). An hSynI enhancer promoter-driven GFP expression cassette was incorporated into the AAV-PHP.B capsid gene-containing AAV vector genome in a TRADE configuration (Figure 3A). This vector genome was packaged into the AAV-PHP.B capsid, and the resulting AAV vector was intravenously injected into two 8-week-old male C57BL / 6J mice (Figure 3B). Twelve days after injection, brain tissue was harvested. Tissues fixed in 4% paraformaldehyde were analyzed by immunofluorescence microscopy. The removed tissues were utilized for RNA extraction and RT-PCR analysis. We confirmed that eGFP was expressed exclusively in neurons (Figures 3C and 3D), indicating that the antisense mRNA transcribed from the cap gene is expressed in a cell type-specific manner. The cap gene antisense mRNA was efficiently recovered by RT-PCR (Figure 3E). Sanger sequencing of the splice junction specific to the antisense mRNA confirmed that the RT-PCR product was indeed derived from the hSynI enhancer promoter-activated antisense mRNA (Figure 3F). Furthermore, Sanger sequencing confirmed the sequence of the PHP.B peptide insertion (Figure 3F). Together, these observations established the ability of the TRADE system to successfully recover the AAV cap sequence from the hSynI enhancer promoter-driven antisense mRNA expressed in AAV vector-transduced brain neurons.
[0042] According to the success rate of the TRADE system, two AAV capsid-directed evolution experiments were performed; one using 8-week-old male C57BL / 6J mice and the other using 8-month-old male rhesus macaques. The AAV9-N272A-hSynI-GFP-TRADE-Lib library was created, which is composed of mutant capsids derived from AAV9 with a GGGS(N8)GGGGS (SEQ ID NO:2) peptide insertion at position Q588, where N8 represents a random 8-mer peptide encoded by (NNK)8. For peptide insertion, Q588 was replaced with each peptide sequence. The diversity of the AAV library was at least 10 7 In mouse-directed evolution experiments, the AAV library was grown at 3 × 10 11 For the second selection, two mice were used to inject the vector genome (vg) at a dose of 1 × 10 12 , 1×10 11 , 1×10 10 , or 1 × 10 9 For the third selection, two mice were used to inject the AAV library at a dose of 1 × 10 vector genome (vg). 11 The AAV library was injected at a dose of 1.5 × 10 per kg. Brain tissue was harvested 12 days after injection and separated into three regions (i.e., cerebrum, cerebellum, and brainstem). Only the cerebrum sample was used for the directed evolution experiment. Total RNA was extracted from the cerebrum, reverse transcribed the RNA using oligo-dT primers, and amplified the peptide region, including the flanking regions, with a pair of cap gene-specific PCR primers. The RT-PCR products were then used to generate the next AAV9-N272A-hSynI-TRADE-Lib plasmid library, which was then used to generate the next AAV9-N272A-hSynI-TRADE-Lib viral library. For the second and third rounds of selection, the AAV9-N272A-hSynI-TRADE-Lib genome lacking the GFP ORF was packaged. For the non-human primate directed evolution experiment, the AAV9-N272A-hSynI-GFP-TRADE-Lib library was cultured at 2.0 × 10 per kg. 12Vg of 5000 ng / ml were injected via the saphenous vein. Twelve days after injection, whole brains were harvested and sliced using brain matrix, treated with RNAlater (Thermo Fisher Scientific), and cryopreserved. Total RNA was then extracted from the following brain regions: frontal cortex, occipital cortex, cerebellum (Purkinje and granular layers), medulla, pons, frontal cortex, hypothalamus, thalamus, cingulate gyrus, caudate nucleus, putamen, hippocampus, and preoptic area. Peptide sequences were retrieved by RT-PCR in the same manner as above, except that nested PCR was performed to obtain sufficient PCR products for downstream Illumina sequencing or Sanger sequencing procedures. For some samples, nested PCR was not performed for Sanger sequencing, and the first PCR products were cloned directly into the plasmid backbone. After three rounds of selection in mice (Table 1) and one round of selection in non-human primates, we identified several potential transduction-enhancing peptides inserted into the AAV9 capsid (Table 2). We then generated a barcoded AAV library and administered it intravenously to two commonly used mouse strains (C57BL / 6J and BALB / cJ) and one rhesus macaque, and then compared the transduction efficiency, tropism / biodistribution, and pharmacokinetics of 26 selected new AAV variants using DNA / RNA barcode-sequence technology previously developed in the Nakai Lab (Adachi et al. Nat Commun 5,3075 (2014); and PCT / US2017 / 068050) (Table 3). As a result, we confirmed the following: (1) Several of the novel variants identified by TRADE technology, particularly AAV9-N272A-TTNLAKNS (HN1) and AAV9-N272A-QQNGTRPS (HN2), performed up to 8-fold better than AAV9 in the brains of C57BL / 6J mice (Figures S14B and S14C). See Table 3 for HNx designations.(2) As previously reported by Hordeaux et al. (Hordeaux et al. 2018), AAV-PHP.B transduced BALB / cJ mouse brains only to levels comparable to AAV9 (Figures S14B and S14C), demonstrating mouse strain dependency for robust neurotropic enhancement of AAV-PHP.B. (3) In contrast, AAV9-N272A-TTNLAKNS (HN1) and AAV9-N272A-QQNGTRPS (HN2) retained robust neuronal transduction in BALB / cJ mice, demonstrating up to 7-fold superior transduction to AAV9 (Figure S14B). (4) In rhesus macaques, many of the new AAV mutants showed up to 4-fold greater enhancement of neuronal transduction than AAV9 in certain brain regions, while AAV-PHP.B transduced non-human primate brains to levels comparable to AAV9. In particular, AAV9-N272A-TTNLAKNS (HN1) showed the best transduction of non-human primate brain in multiple brain regions (Figures 14C and 14D). (5) All of the AAV9-N272A-derived variants, including HN1, HN2, and HN3, showed various degrees of liver-detargeting properties in mice and rhesus monkeys (Figure 17A). (6) AAV9-N272A-TTNLAKNS (HN1) and AAV9-N272A-QQNGTRPS (HN2) could transduce cells with up to 17-fold better lung hSynI enhancer promoter transcription activity than mouse AAV9 (Figure 17B, Tables 4 and 6). (7) AAV9-N272A-TTNLAKNS(HN1) shows a lower degree of vector genome spread to peripheral organs compared to AAV9 (Figures 17C and 17D). AAV barcode-sequence data are summarized in Tables 4-9. Representative data presented in Tables 4-9 are also shown in graph format in Figures 14 and 17.
[0043] [Table 1-1]
[0044] [Table 1-2]
[0045]
Table 1-3
[0046]
Table 1-4
[0047]
Table 2
[0048]
Table 3-1
[0049]
Table 3-2
[0050]
Table 4
[0051]
Table 5
[0052]
Table 6
[0053]
Table 7
[0054]
Table 8
[0055]
Table 9
[0056]
Table 10
[0057] During experiments, when the AAV9 cap gene ORF was expressed in the antisense orientation in HEK293 or Neuro2a cells, the majority of the antisense AAV9 cap gene mRNA-derived RT-PCR products were truncated at approximately 1.7 kb (Figure 4), which was not the case for RNA recovered from AAV-PHP.B-hSynI-GFP-TRADE-transduced mouse brain tissue (Figure 3). Sequencing of the truncated RT-PCR products revealed that a 1694 bp long region was missing within the AAV9 cap ORF (Figure 5). Without wishing to be bound by any particular theory, the truncation appears to result from a splicing event based on the observation that we were able to identify splice donor and splice acceptor sites in PCR products with the general characteristics of exon-intron junctions. Interestingly, sequence alignment studies revealed that cryptic splice donor and acceptor sites, with the general characteristics of exon-intron junctions, could also be identified in many naturally occurring AAV serotypes in regions corresponding to those identified in the AAV9 cap gene, and that they are highly conserved (Figure 6). This indicates that splicing can occur not only in the AAV9 cap ORF-derived antisense mRNA, but potentially also in the cap ORF-derived antisense mRNA of other AAV strains. To date, splicing has been found to occur in the AAV3 cap ORF-derived antisense mRNA when expressed under the control of the human liver-specific promoter (LSP) in HepG2 cells. Although full characterization has not been completed, preliminary RT-PCR using RT primers specific for the antisense mRNA produced truncated RT-PCR products in addition to the full-length, unspliced product. Sequencing analysis of the two truncated RT-PCR products revealed that multiple splicing events were present in the antisense mRNA (Figure 7). Sequencing alignment studies identified additional potential splice donor and acceptor sites (Figures 8 and 9).We also confirmed splicing events in antisense mRNAs derived from the AAV1 capped ORF when the antisense mRNAs were transcribed by the hSynI enhancer promoter in HEK293 or Neuro2a cells (Figure 10). Many of the identified splice donor sites (GT / CA) and splice acceptor sites (AG / TC) are highly conserved across different serotypes, indicating that these sites are potentially also utilized as splice donor and acceptor sites in unexplored AAV serotypes. Indeed, splicing of antisense mRNA transcripts of AAV1, AAV3, and AAV9 capped ORFs was confirmed to use several common splice donor and acceptor sites (Figure 10). To date, splicing of antisense mRNA transcripts of AAV5 capped ORF has yet to be observed. Splicing events in antisense mRNAs of AAV capped ORFs have yet to be investigated for serotypes other than AAV1, 3, 5, and 9.
[0058] Potential splicing of the antisense mRNA from the capped ORF, while scientifically interesting, may hinder the TRADE system when the full-length capped ORF sequence needs to be recovered from the antisense mRNA. To overcome this potential problem, silent mutations were introduced that presumably disrupt conserved sequences at the exon-intron junctions and branch points. To demonstrate the proof of principle of this approach, silent mutations were introduced into the AAV9 capped ORF contained in the plasmid, pAAV9-N272A-PHP.B-hSyn1-GFP-TRADE, that disrupt the splice acceptor (SA) consensus sequence (pAAV9NS1 construct), the splice donor (SD) consensus sequence (pAAV9NS2 construct), and the consensus sequences for both the splice acceptor and splice donor (pAAV9NS3 construct). Note that NS is an abbreviation for "unspliced." The methods used to disrupt these consensus sequences are described below.
[0059] Codon-optimize the AAV cap ORF sequence for human cell expression.
[0060] To identify potential splice donors and splice acceptors in antisense mRNAs derived from capped ORFs, we develop and use a unique database of potential splice donor and splice acceptor sites in antisense mRNAs based on our experimental and bioinformatics observations (i.e., Figures 5, 6, 7, 8, 9, and 10).
[0061] Use codon-optimized sequences to disrupt the GT (splice donor) and / or AG (splice acceptor) consensus sequences by changing at least one nucleotide. If codon-optimized sequences are not available, use alternative nucleotides that can disrupt the consensus sequences.
[0062] The stretch of T's upstream of the splice acceptor site is removed by introducing silence mutations based on the codon-optimized sequence. If the codon-optimized sequence is not sufficient to disrupt the stretch of T's, alternative nucleotides are used.
[0063] Also, avoid exon-terminal Gs whenever possible.
[0064] Potential branch points are identified using several programs that can predict branch points (e.g., Human Splicing Finder (Desmet, Hamroun et al. 2009)) and replaced with codon-optimized sequences. If the degree of nucleotide change achievable with this method is not sufficient, alternative nucleotides are introduced to disrupt the potential branch points.
[0065] In this way, we created capped ORFs for AAV9NS1 (SA, disrupted), AAV9NS2 (SD, disrupted), and AAV9NS3 (both SD and SA, disrupted) (Figure 9). These ORFs in the antisense orientation were expressed by transient plasmid transfection under the control of the hSynI enhancer promoter in Neuro2a cells, and the antisense transcripts were analyzed by RT-PCR. This experiment revealed that splicing could be effectively suppressed in all of the NS1, NS2, and NS3 capped ORFs (Figure 10). Note that even when splicing occurred in the capped ORF-derived antisense mRNA, it was still possible to recover the relatively small peptide insertion region of the capped ORF from the pre-mRNA by RT-PCR.
[0066] The TRADE method described herein uses antisense mRNA to evolve viral proteins, establishing proof of principle and showing that the method is successfully reduced to practice. The TRADE system can also produce viruses and utilize mRNA in the sense orientation, as long as potential expression of viral proteins in target cells during the directed evolution procedure does not prevent the continuous evolution of new capsids.
[0067] Additional information related to nucleic acid splicing and AAV can be found in Desmet et al., Nucleic Acids Res 37, e67 (2009); Matsuzaki et al., Neurosci Lett 665, 182-188 (2018); and Hordeaux et al., Mol Ther 26, 664-668 (2018).
[0068] All references cited in this disclosure are incorporated by reference in their entirety.
Claims
1. A nucleic acid, the nucleic acid comprising: a Parvoviridae genome flanked by ITR sequences, the Parvoviridae genome comprising a Parvoviridae intron, a Parvoviridae cap gene, and a first polyadenylation signal in a first orientation; a first promoter in said first orientation driving expression of a Parvoviridae cap gene in the presence of adenoviral helper functions; A nucleic acid comprising a second promoter and a second polyadenylation signal in a second orientation that is antisense to the first orientation, the second polyadenylation signal being positioned to cause termination of antisense mRNA transcription of a Parvoviridae cap gene.
2. The nucleic acid of claim 1 , wherein the second promoter is a cell type specific promoter.
3. The nucleic acid of claim 1 , wherein the second promoter is a ubiquitous promoter.
4. The nucleic acid according to any one of claims 1 to 3, wherein the Parvoviridae genome is an AAV genome comprising an AAV intron and an AAV cap gene.
5. The nucleic acid of claim 4, wherein the AAV cap gene is a wild-type AAV cap gene.
6. 6. The nucleic acid of claim 5, wherein the AAV cap gene sequence is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, or other naturally occurring AAV isolated cap gene sequence.
7. The nucleic acid of claim 4 , wherein the AAV cap gene is a recombinant AAV cap gene.
8. The nucleic acid of claim 4, wherein the AAV cap gene is one of a library of diverse AAV cap genes.
9. 5. A nucleic acid library comprising a plurality of nucleic acids according to claim 4, wherein the nucleic acids comprise a plurality of unique AAV cap gene sequences.
10. The nucleic acid library comprises about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 or 10 8 10. The nucleic acid library of claim 9, comprising more than 10 unique AAV cap gene sequences.
11. The nucleic acid according to any one of claims 1 to 8, further comprising a gene of interest in the second orientation.
12. The nucleic acid of any one of claims 4 to 8 or 11, wherein the second polyadenylation signal is located within an AAV intron.
13. 12. The nucleic acid of any of claims 4 to 8 or 11, wherein the second polyadenylation signal is positioned such that the cap gene is correctly translated into a full-length capsid protein in the first orientation and the cap gene is correctly transcribed into an antisense mRNA comprising a full-length AAV cap gene coding sequence.
14. 1. A method for identifying an AAV vector having a cap gene sequence that has an increased ability to transduce cells from a tissue of interest compared to at least one other AAV vector having a different cap gene sequence, the method comprising: A step of preparing a first round AAV TRADE vector library by introducing the nucleic acid library according to claim 9 or 10 into an AAV packaging cell line and recovering the first round AAV TRADE vector library from the packaging cell line; injecting the first round AAV TRADE vector library into one or more animals; recovering the cap gene sequence of the AAV vector that is enriched in the cells of the target tissue of the animal; preparing a second round AAV TRADE nucleic acid library comprising the recovered cap gene sequences of the enriched AAV vectors, introducing the library into an AAV packaging cell line, and recovering a second round AAV TRADE vector library from the packaging cell line; performing a second round of enrichment by injecting the second round of AAV TRADE vector library into one or more animals and recovering cap gene sequences that are enriched in cells of a tissue of interest in the animals; Identifying the enriched AAV cap gene sequences after the first round of enrichment, after the second round of enrichment, and after any round of enrichment thereafter.
15. 1. A method for producing an AAV TRADE vector, or an AAV TRADE vector library, the method comprising: A method comprising the steps of: introducing a nucleic acid according to any one of claims 4 to 8 or 11 to 13, or a nucleic acid library according to claim 9 or 10, into an AAV packaging cell line; and recovering an AAV TRADE vector or an AAV TRADE vector library from the packaging cell line.
16. 1. A method for determining a novel cap gene sequence of an AAV vector having an increased ability to transduce cells of a target tissue, the method comprising: Identifying an AAV vector by the method of claim 14; recovering the antisense mRNA comprising the cap gene sequence; determining a new cap gene sequence.
17. The method of claim 16, wherein the antisense mRNA is recovered using RT-PCR.
18. 18. The method of claim 16 or 17, further comprising determining the cap gene sequence.
19. An AAV vector comprising the nucleic acid according to any one of claims 4 to 8 or 11 to 13.
20. A nucleic acid, the nucleic acid comprising: a Parvoviridae genome flanked by ITR sequences, the Parvoviridae genome comprising a Parvoviridae intron, a Parvoviridae cap gene, and a first polyadenylation signal in a first orientation; a first promoter in said first orientation driving expression of a Parvoviridae cap gene in the presence of adenoviral helper functions; and a second promoter in said first orientation that drives expression of a Parvoviridae cap gene in the absence of adenoviral helper functions.
21. 21. The nucleic acid of claim 20, wherein the second promoter is a cell type specific promoter.
22. The nucleic acid of claim 20 , wherein the second promoter is a ubiquitous promoter.
23. The nucleic acid of any one of claims 20 to 22, wherein the Parvoviridae cap gene is a wild-type AAV cap gene.
24. 24. The nucleic acid of claim 23, wherein the AAV cap gene sequence is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, or other naturally occurring AAV isolated cap gene sequence.
25. The nucleic acid of any one of claims 20 to 22, wherein the Parvoviridae cap gene is a recombinant AAV cap gene.
26. The nucleic acid of any one of claims 20 to 25, wherein the Parvoviridae cap gene is one of a library of diverse AAV cap genes.
27. 21. A nucleic acid library comprising a plurality of nucleic acids according to claim 20, wherein the nucleic acids comprise a plurality of unique Parvoviridae cap gene sequences.
28. The nucleic acid library comprises about 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 or 10 8 28. The nucleic acid library of claim 27, comprising more than 10 unique AAV cap gene sequences.
29. The nucleic acid according to any one of claims 20 to 26, further comprising a gene of interest.
30. 1. A method for identifying an AAV vector having a cap gene sequence that has an increased ability to transduce cells from a tissue of interest compared to at least one other AAV vector having a different cap gene sequence, the method comprising: Preparing a first round AAV TRADE vector library by introducing the nucleic acid library of claim 27 or 28 into an AAV packaging cell line and recovering the first round AAV TRADE vector library from the packaging cell line; injecting the first round AAV TRADE vector library into one or more animals; recovering the cap gene sequence of the AAV vector that is enriched in the cells of the tissue of interest in the animal; preparing a second round AAV TRADE nucleic acid library containing the enriched AAV vector cap gene sequences, introducing the library into an AAV packaging cell line, and recovering the second round AAV TRADE vector library from the packaging cell line; performing a second round of enrichment by injecting the second round of AAV TRADE vector library into one or more animals and recovering cap gene sequences that are enriched in cells of a tissue of interest in the animals; Identifying the enriched AAV cap gene sequences after the first round of enrichment, after the second round of enrichment, and after any round of enrichment thereafter.
31. 1. A method for producing an AAV TRADE vector, or an AAV TRADE vector library, the method comprising:
30. A method comprising the steps of: introducing a nucleic acid according to any one of claims 23 to 26 or 29, or a nucleic acid library according to claim 27 or 28, into an AAV packaging cell line; and recovering an AAV TRADE vector or an AAV TRADE vector library from the packaging cell line.
32. 1. A method for determining a novel cap gene sequence of an AAV vector having an increased ability to transduce cells of a target tissue, the method comprising: Identifying an AAV vector by the method of claim 30; recovering the sense mRNA comprising the cap gene sequence; determining a new cap gene sequence.
33. The method of claim 32, wherein the sense mRNA is recovered using RT-PCR.
34. 34. The method of claim 32 or 33, further comprising determining the cap gene sequence.
35. 30. An AAV vector comprising the nucleic acid of any one of claims 23 to 26 or 29.
36. A nucleic acid according to any one of claims 1 to 8 or 11 to 13, further comprising at least one mRNA splicing suppressor mutation in said second orientation.
37. 37. The nucleic acid of claim 36, wherein the at least one mRNA splicing suppressor mutation comprises an alteration of one or more nucleotides located within 10 nucleotides of a splice donor and / or splice acceptor site.
38. 38. The nucleic acid of claim 36 or 37, wherein the alteration does not change the amino acid sequence encoded by the AAV cap gene.
39. 1. An AAV cap ORF sequence comprising one or more of the following mutations in the exon-intron junction of the splice donor site: AAV1 VP1 cap ORF 1009-CTTAC(concatenation)CAGCA-1018* (SEQ ID NO:199) AAV3 VP1 cap ORF 1006-CTTAC(concatenation)CAGCA-1015* (SEQ ID NO:199) AAV1 VP1 Cap ORF 1228-TTTAC(junction)CTTCA-1237 (SEQ ID NO:200) AAV3 VP1 Cap ORF 1237-TATAC(ligation)CTTCG-1246 (SEQ ID NO:201) AAV1 VP1 Cap ORF 1331-ATTAC(junction)CTGAA-1340 (SEQ ID NO:202) AAV1 VP1 Cap ORF 1434-GCTAC(ligation)CTGGA-1443 (SEQ ID NO:203) AAV1 VP1 Cap ORF 1502-TTTAC(junction)CTGGA-1510 (SEQ ID NO:204) AAV1 VP1 Cap ORF 1803-ATTAC(junction)CTGGC-1812 (SEQ ID NO:205) AAV3 VP1 Cap ORF 1803-CTTAC(junction)CTGGC-1812 (SEQ ID NO:206) AAV1 VP1 Cap ORF 1835-TGTAC(junction)CTGCA-1844 (SEQ ID NO:207) AAV1 VP1 cap ORF 2189-GTTAC(ligation)CTTAC-2198 (SEQ ID NO:208) AAV9 VP1 Cap ORF 2189-GATAC(ligation)CTGAC-2198 (SEQ ID NO:209) AAV1 VP1 cap ORF 2194-CTTAC(junction)CCGTC-2203 (SEQ ID NO:210) AAV3 VP1 has the ORF 2194-CTCAC(concatenation)ACGAA-2203 (SEQ ID NO:211). (*The nucleotide numbers are different but they are the corresponding nucleotides of the AAV cap ORF in the sequence alignment.)
40. 1. An AAV cap ORF sequence comprising one or more of the following mutations in the exon-intron junction of the splice donor site: AAV1 VP1 cap ORF 305-AGCGT(ligation)CTGCA-314 (SEQ ID NO:212) AAV1 VP1 cap ORF 414-GGCTC(junction)CTGGA-423 (SEQ ID NO:213) AAV3 VP1 cap ORF 414-GGCTC(junction)CTGGA-423 (SEQ ID NO:213) AAV1 VP1 cap ORF 495-GCCCG(junction)CTAAA-504 (SEQ ID NO:214) AAV9 VP1 cap ORF 495-GCCCG(junction)CTAAA-504 (SEQ ID NO:214) AAV3 VP1 cap ORF 1133-TCACC(junction)CTGAA-1142 (SEQ ID NO:215) AAV1 VP1 Cap ORF 1181-ACTGC(junction)CTGGA-1190 (SEQ ID NO:216) AAV1 VP1 cap ORF 1331-ATTAC(junction)CTGAA-1340** (SEQ ID NO:202) AAV3 VP1 cap ORF 1328-ACTAC(ligation)CTGAA-1337** (SEQ ID NO:217) AAV1 VP1 cap ORF 1464-CGTTT(junction)CTAAA-1473 (SEQ ID NO:218) AAV1 VP1 cap ORF 1653-AAACA(junction)CTGCA-1662 (SEQ ID NO:219) AAV1 VP1 cap ORF 2054-GGGAG(junction)CTGCA-2063 (SEQ ID NO:220) AAV3 VP1 cap ORF 2054-GGGAG (junction) CTACA-2063 (SEQ ID NO: 463) (**Although the nucleotide numbers are different, they are the corresponding nucleotides of the AAV cap ORF in the sequence alignment.)
41. An AAV cap ORF sequence comprising one or more of the following mutations in the exon-intron junctions of the splicing donor or splicing acceptor sites: Splice Donor AAV1 VP1 cap ORF 1009-CTTAC(concatenation)CAGCA-1018* (SEQ ID NO:199) AAV3 VP1 cap ORF 1006-CTTAC(concatenation)CAGCA-1015* (SEQ ID NO:199) AAV1 VP1 Cap ORF 1228-TTTAC(junction)CTTCA-1237 (SEQ ID NO:200) AAV3 VP1 Cap ORF 1237-TATAC(ligation)CTTCG-1246 (SEQ ID NO:201) AAV1 VP1 Cap ORF 1331-ATTAC(junction)CTGAA-1340 (SEQ ID NO:202) AAV1 VP1 Cap ORF 1434-GCTAC(ligation)CTGGA-1443 (SEQ ID NO:203) AAV1 VP1 Cap ORF 1502-TTTAC(junction)CTGGA-1510 (SEQ ID NO:204) AAV1 VP1 Cap ORF 1803-ATTAC(junction)CTGGC-1812 (SEQ ID NO:205) AAV3 VP1 Cap ORF 1803-CTTAC(junction)CTGGC-1812 (SEQ ID NO:206) AAV1 VP1 Cap ORF 1835-TGTAC(junction)CTGCA-1844 (SEQ ID NO:207) AAV1 VP1 cap ORF 2189-GTTAC(ligation)CTTAC-2198 (SEQ ID NO:208) AAV9 VP1 Cap ORF 2189-GATAC(ligation)CTGAC-2198 (SEQ ID NO:209) AAV1 VP1 cap ORF 2194-CTTAC(junction)CCGTC-2203 (SEQ ID NO:210) AAV3 VP1 cap ORF 2194-CTCAC(concatenation)ACGAA-2203 (SEQ ID NO:211) Splice acceptor AAV1 VP1 cap ORF 305-AGCGT(ligation)CTGCA-314 (SEQ ID NO:212) AAV1 VP1 cap ORF 414-GGCTC(junction)CTGGA-423 (SEQ ID NO:213) AAV3 VP1 cap ORF 414-GGCTC(junction)CTGGA-423 (SEQ ID NO:213) AAV1 VP1 cap ORF 495-GCCCG(junction)CTAAA-504 (SEQ ID NO:214) AAV9 VP1 cap ORF 495-GCCCG(junction)CTAAA-504 (SEQ ID NO:214) AAV3 VP1 cap ORF 1133-TCACC(junction)CTGAA-1142 (SEQ ID NO:215) AAV1 VP1 Cap ORF 1181-ACTGC(junction)CTGGA-1190 (SEQ ID NO:216) AAV1 VP1 cap ORF 1331-ATTAC(junction)CTGAA-1340** (SEQ ID NO:202) AAV3 VP1 cap ORF 1328-ACTAC(ligation)CTGAA-1337** (SEQ ID NO:217) AAV1 VP1 cap ORF 1464-CGTTT(junction)CTAAA-1473 (SEQ ID NO:218) AAV1 VP1 cap ORF 1653-AAACA(junction)CTGCA-1662 (SEQ ID NO:219) AAV1 VP1 cap ORF 2054-GGGAG(junction)CTGCA-2063 (SEQ ID NO:220) AAV cap ORF sequence, including AAV3 VP1 cap ORF 2054-GGGAG(junction)CTACA-2063 (SEQ ID NO:463).
Citation Information
Patent Citations
aav vectors identified by novel high-efficiency libraries
JP2017534601A
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
WO2017100671A1
Methods and compositions for gene transfer across the vasculature
WO2018152333A1
